Seth H. Lourie, MD
To the Editors: Epstein and colleagues (1) raise some interesting and provocative points regarding gold therapy. Their presentation of the data, however, raises some serious questions of bias in interpretation. Specifically, one third of the patients are described as having received parenteral gold during the year before the study. This group is not further separated from the rest of the cohort when discussing patient characteristics at the beginning of the study. There is also a peculiar distribution of the number of patients who received gold during the first year of the study when compared with those who apparently began gold
Lourie SH. Gold Therapy for Rheumatoid Arthritis. Ann Intern Med. ;115:155–156. doi: 10.7326/0003-4819-115-2-155
Download citation file:
Published: Ann Intern Med. 1991;115(2):155-156.
Rheumatoid Arthritis, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use